Loading...
Loading...
Genzyme,
a Sanofi company
SNY, announced today that
Health Canada has approved Lemtrada (alemtuzumab) for the management of
adult patients with relapsing remitting multiple sclerosis (RRMS), with
active disease defined by clinical and imaging features, who have had an
inadequate response to interferon beta or other disease-modifying
therapies.
“Lemtrada is an important new treatment option for Canadians with MS. It
has impressive effectiveness following two treatment courses for those
patients with active relapsing MS,” said Dr. Anthony Traboulsee,
Associate Professor of Neurology and Medical Director of the UBC
Hospital MS Clinic of Vancouver Coastal Health. “Our own local
experience in treating 35 patients through clinical
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in